Insilico's AI-designed TEAD inhibitor secures FDA fast track for mesothelioma

Insilico Medicine's AI-designed pan-TEAD inhibitor ISM6331 has received Fast Track Designation from the US FDA for the treatment of advanced mesothelioma, supporting accelerated clinical development and regulatory review. This designation is the first Fast Track granted to any program in Insilico's pipeline and allows for more frequent FDA interaction and potential faster approval pathways.

This Wire brief sits within Fusion42's coverage of Drug Discovery.